In this paper I shall discuss three topics concerning immunization against infectious diseases in general practice: (1) The schedule of immunization in childhood. (2) The use of new and future vaccines. (3) The possibility of protecting individuals against a wider range of common but troublesome infections which occur in the community.
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Schedules of
Immunization in Childhood The schedules proposed in 1959 have recently been superseded by a new schedule which is in use in the clinics and which we are asked to implement. We need to maintain a high degree of immunity in our population against the severe but now rare infections such as smallpox, diphtheria and poliomyelitis. We must also aim at protecting the population against tetanus, if only to avoid troublesome injections each time small injuries are sustained by individuals.
Our vaccines must not only be safe and effective but also have a good acceptance rate by the parents. I feel myself that the older schedule starting at three months has many advantages, not least that infants are protected against pertussis at an early age. This disease is, of course, most lethal in the first year of life and we should aim at protecting infants as young as possible since it is difficult to eradicate the disease from the population with our present vaccines. The other advantage of the older schedule is that mothers, bring their children early and are more likely to continue a programme if it is started in this wayearly in the infant's career. I realize that this may "Requests for reprints may be sent to: 52 High Street, Epsom, Surrey be difficult to do in some areas where the standards of care and co-operation are not very high, but it should be possible to continue the programme by giving the measles vaccine at 1 year, a booster at 18 months and vaccination against smallpox during the second year.
The safety of vaccines is now assured by our colleagues who undertake the laborious testing of the products. The dangers of the past with their sad history of accidents and disasters have tecently been very well shown by Sir Graham Wilson (1967) . We should all remember the background and history of immunization every time we inoculate a child.
New Vaccines
Vaccines against measles and rubella have a fairly short history. The use of measles vaccine still seems hesitant and this probably reflects the attitude of many doctors who are not yet quite sure of its value; there has been a recent set-back in its use when one batch had to be withdrawn.But measles is often a severe disease, especially in young adults, and we should make full use of this vaccine at the end of the first year of life, and also ensure that young adults who may have escaped childhood infection are offered the vaccine. This may mean testing for antibodies before giving the vaccine, but the laboratories are now able to do this readily.
Rubella vaccine is also going to be a very useful agent which should be effective and, according to American reports, long-lasting in its protection. The consequences of infection of a feetus are so serious that we are left with the ultimate responsibility for termination, which is a method of control to be avoided We must therefore consider testing adolescent girls for antibodies and offering vaccine at this stage.
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Whether we should use vaccines against mumps and chickenpox, if and when they are developed, will depend entirely on their efficiency and the duration of immunity produced. Mumps can be an unpleasant illness, especially in the adolescent, and one would like to have the means to protect the growing boy without antibodies to mumps against the possibility of orchitis. In addition, encephalitis, fortunately usually mild and not causing any sequelx, is not uncommon in this age group.
Chickenpox can also be a serious illness in the adult, with the threat of severe pneumonia and encephalitis in a minority of cases. If parents have escaped this infection in childhood, then it would be excellent if we could protect them during an epidemic in which their children may pass the infection on to them. I would like to have vaccines against these two diseases to use in a selective manner to protect older individuals when epidemics occur.
Acute Respiratory Infections These cause much morbidity for, although most infections are mild, severe lower respiratory tract infections do occur, mainly at extremes of life. I suspect that influenza A virus causes more illness in the community than we think. Mortality rates from all causes rise during an epidemic, but this effect is only really obvious if the epidemic is a large one. We have just experienced such an outbreak where many young adults were severely affected and where otherwise healthy persons had a long convalescence after a clinical attack of influenza. How much greater was the effect in many cases in chronically ill patients! In spite of disappointments in the past when vaccine has been used, the evidence shows that a saline vaccine made from the prevailing type of virus provides a worthwhile protection if it is given annually. This is most easily seen in an institution such as a boarding school where an unprotected population may have an attack rate of 75 % or more. Records from schools have shown a good correlation over the past few years between the degree of vaccination of the population and its freedom from influenza (Turtle 1968 ). Vaccines can be produced quickly, as was the Hong Kong vaccine in 1968. I think, therefore, that we should give these vaccines more freely to persons at risk, and here I include hospital nurses especially, to those in semiclosed communities such as boarding schools, and to our chronically ill patients, especially those with chronic bronchitis. The reaction rate has been acceptable to most individuals but it is best to exclude those with an allergic history as they may develop a reaction to the vaccine itself or to egg protein.
In many other acute respiratory infections the existence of so many different serotypes and a complicated epidemiological situation makes control difficult. For example, the principal agent of common colds is the rhinovirus group which contains more than 80 different serotypes with little or no cross-reaction. Studies of the types circulating in the community, such as the one carried out by Hamre in Chicago (1968), do not even reveal a few commonly encountered types. The picture is of the presence of a large number of different serotypes, each causing immunity in the infected individual, but leaving him open to another infection with other varieties. It is unlikely, therefore, that we can control these with the use of vaccines, which in any case would have to have an enormous number of components.
On the other hand, para-influenza viruses occur commonly as only three serotypes, and as these cause severe croup, bronchitis or pneumonia in children it would seem logical to try and develop vaccines against them. Some success has been had in Washington by Chanock et al. (1967) and I think it may prove that an effective vaccine against these agents will prevent a good deal of severe infection in infancy. Our methods of detection of virus infection are not very sensitive and surveys of childhood infections may have underestimated the amount due to any one agent. We may come nearer the goal than seems likely at present, but these surveys should be continued.
Respiratory syncytial virus (RSV) is the other pathogen of the lower respiratory tract in infancy causing much severe disease, especially in industrial areas among lower economic groups. Unfortunately, experience with a vaccine made from this organism in Washington (Kim et al. 1969) has shown that infants may become sensitized so that if they are infected a more severe illness is produced than would have occurred if they had not had the vaccine. In this respect, it is similar to the effect of killed measles vaccine which, when given alone, left children open to severe attacks of this disease. It is possible, however, that a live attenuated RSV vaccine would be effective and safe, and would protect children against RSV lower respiratory tract infections at this susceptible age. This is a type of illness for which we really do need protection for infants. This is about as far as vaccines against respiratory infections have gone. Vaccines against illnesses due to other groups, such as adeno-Section ofGeneralPractice 811 viruses, Coxsackie and echo viruses and Mycoplasma pneumonia,, if available, would be difficult to apply either because of the sporadic nature of the infections or because they come in unpredictable epidemics at long intervals. Infective hepatitis can be dealt with by immunoglobulin injections for close contact cases. For infective mononucleosis there seems at present to be no useful management and its apparent association with the Epstein-Barr virus and lymphoma means that much more work will have to be done on the epidemiology before we can understand its behaviour or attempt to control it. 
Assessing Immunization Procedures
The extensive use of immunization is one of the most striking features of modem infectious disease control. No less than seven different vaccines, diphtheria, tetanus, poliomyelitis, pertussis, smallpox, measles and tuberculosis, are included in the current immunization schedule. To these must be added influenza vaccine which is employed extensively though not consistently, and immunoglobulin to produce passive immunization. Rubella vaccine has recently been licensed and will doubtless be used on a large scale very soon. A vaccine against mumps has undergone successful trials in the United States of America.
The widespread use of vaccines to control infectious diseases, while proving highly effective, has raised a variety of problems which it has not always been possible to solve satisfactorily. No vaccine is entirely safe and the risks from each have to be balanced against its expected benefits to the individual and the community. For each vaccine such assessments usually require extensive investigations sometimes prolonged for many years. Indeed, although short-term assessments can be made within a year or two, the long-term benefits and hazards for each new vaccine cannot possibly be known at the time when the vaccine is introduced. Moreover, a first favourable assessment may have to be repeated, since the usefulness of a vaccine may decrease with time due to changing epidemiological circumstances.
During the last few years increasing attention has been paid to these and related problems by the Public Health Laboratory Service (PHLS) which has undertaken several studies into current problems of immunization. These studies have depended on the close co-operation of three groups. First, physicians responsible for the clinical work of the investigation who are usually general practitioners, medical officers of health, student health physicians or individual medical officers; secondly, microbiologists responsible for the laboratory aspects; and finally the Epidemiological Research Laboratory, whose staff coordinate the investigation and design and process the records.
The PHLS investigations have included trials of a new vaccine (measles) before its introduction for general use, an assessment of an established procedurethe prevention of rubella in pregnant contacts by immunoglobulin, and a re-assessment of a vaccine (pertussis) to examine the effectiveness of the current batches. General practitioners played a leading part in all three investigations.
Measles Vaccine
By 1964 accumulated experience from the USA and pilot studies in England indicated that mass immunization against measles was both feasible and of considerable potential value. However, the safety and efficacy of measles vaccines when used on a large scale had not been studied in England.
Among other problems there were doubts about the duration of the protection conferred, the reactions to the vaccine and the value of giving a preliminary dose of killed vaccine. Moreover, there were widespread doubts as to whether mass vaccination was warranted for a disease as mild as measles. The trial had therefore to take into account the reactions to the vaccine, the efficacy of the vaccine and the severity of measles occurring in an unvaccinated control group.
The trial was made in twelve areas. The medical officers of health concerned invited parents with children aged 10 months to 2 years to take part and eventually about 47,000 infants were allocated to receive either live vaccine of the Schwartz strain prepared by Glaxo, or killed vaccine followed by live vaccine, or to remain unvaccinated as controls. Three weeks after the date of vaccination each home was visited by a nurse or health visitor to
